
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - New long-term data with the topical immunomodulator tacrolimus(Protopic) and the skin-selective inflammatory cytokine inhibitor pimecrolimus(Elidel) demonstrate efficacy as maintenance therapies in the treatmentof atopic dermatitis in children. Data with pimecrolimus show safety andefficacy for as long as 26 weeks in infants as young as three months, LawrenceEichenfield, M.D., said at the annual meeting of the American Academy ofDermatology.